Pacira BioSciences (NASDAQ:PCRX) SVP Lauren Riker Sells 6,000 Shares of Company Stock

Pacira BioSciences, Inc. (NASDAQ:PCRX) SVP Lauren Riker sold 6,000 shares of the firm’s stock in a transaction on Thursday, October 8th. The shares were sold at an average price of $36.32, for a total transaction of $217,920.00. Following the sale, the senior vice president owned 62,284 shares in the company, valued at $2,262,154.88. The trade was a 8.79% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Pacira BioSciences Stock Down 0.2%

PCRX opened at $36.31 on Friday. The stock has a market cap of $1.45 billion, a price-to-earnings ratio of 103.75 and a beta of 0.25. The company has a debt-to-equity ratio of 0.54, a quick ratio of 3.94 and a current ratio of 5.04. The firm’s fifty day moving average is $25.56 and its 200 day moving average is $24.59. Pacira BioSciences, Inc. has a fifty-two week low of $18.80 and a fifty-two week high of $36.46.

Pacira BioSciences (NASDAQ:PCRX) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $0.73 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.65 by $0.08. The business had revenue of $192.40 million during the quarter, compared to analyst estimates of $191.06 million. Pacira BioSciences had a return on equity of 9.68% and a net margin of 1.96%. Pacira BioSciences’s revenue for the quarter was up 6.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.74 EPS. On average, sell-side analysts forecast that Pacira BioSciences, Inc. will post 1.86 earnings per share for the current fiscal year.

Pacira BioSciences News Roundup

Here are the key news stories impacting Pacira BioSciences this week:

• Positive Sentiment: Viatris agreed to buy Pacira for $36.50 per share in cash, valuing the equity at approximately $1.65 billion. The transaction gives shareholders a defined exit price and is expected to close by the end of 2026, subject to customary conditions. Viatris acquisition announcement
• Positive Sentiment: Viatris will add Pacira’s marketed non-opioid pain therapies, EXPAREL and ZILRETTA, along with a clinical-stage gene therapy candidate. Viatris expects the deal to expand its pain portfolio and be immediately accretive to its financial guidance metrics.
• Neutral Sentiment: RBC said a superior competing bid is unlikely, reducing the prospect of a higher offer but also lowering takeover uncertainty. The stock’s upside is therefore largely capped near the $36.50 consideration unless another bidder emerges. RBC superior bid analysis
• Neutral Sentiment: Analyst actions largely reflect the announced deal: JPMorgan upgraded PCRX to neutral, while RBC and Truist raised targets to $36.50 and maintained sector perform or hold ratings. HC Wainwright maintained neutral with a $36.50 target, and Jefferies kept hold with a $36.00 target.
• Negative Sentiment: Several shareholder-rights law firms are investigating whether Pacira’s board obtained fair value and conducted an adequate sale process. These investigations could create legal or procedural distractions, although no wrongdoing has been established. Shareholder investigation

Analyst Ratings Changes

Several analysts recently issued reports on PCRX shares. Leerink Partners assumed coverage on Pacira BioSciences in a research note on Wednesday, September 9th. They set a “market perform” rating and a $28.00 target price on the stock. Jefferies Financial Group restated a “hold” rating and issued a $36.00 price target on shares of Pacira BioSciences in a research note on Thursday. Wall Street Zen raised shares of Pacira BioSciences from a “buy” rating to a “strong-buy” rating in a report on Saturday, September 26th. Needham & Company LLC cut shares of Pacira BioSciences from a “buy” rating to a “hold” rating in a research report on Thursday. Finally, Royal Bank Of Canada boosted their target price on shares of Pacira BioSciences from $25.00 to $36.50 and gave the stock a “sector perform” rating in a report on Friday. One analyst has rated the stock with a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Pacira BioSciences currently has a consensus rating of “Hold” and a consensus target price of $33.33.

Institutional Investors Weigh In On Pacira BioSciences

A number of hedge funds have recently made changes to their positions in PCRX. Integrated Wealth Concepts LLC boosted its stake in Pacira BioSciences by 8.6% during the second quarter. Integrated Wealth Concepts LLC now owns 43,764 shares of the company’s stock valued at $1,110,000 after buying an additional 3,482 shares during the last quarter. Baird Financial Group Inc. bought a new stake in Pacira BioSciences in the 2nd quarter worth approximately $213,000. Amundi increased its stake in Pacira BioSciences by 16.2% in the 2nd quarter. Amundi now owns 15,894 shares of the company’s stock worth $403,000 after acquiring an additional 2,210 shares during the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in shares of Pacira BioSciences during the 2nd quarter worth approximately $851,000. Finally, Three Seasons Wealth LLC raised its holdings in shares of Pacira BioSciences by 43.6% during the 2nd quarter. Three Seasons Wealth LLC now owns 62,942 shares of the company’s stock worth $1,597,000 after acquiring an additional 19,107 shares in the last quarter. 99.73% of the stock is currently owned by hedge funds and other institutional investors.

About Pacira BioSciences

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain-management products. The company’s portfolio is designed to help manage acute and chronic pain while reducing reliance on traditional opioid therapies.

Its principal product is EXPAREL, an extended-release formulation of bupivacaine used to provide postsurgical pain relief. Pacira also markets ZILRETTA, an extended-release corticosteroid injection for osteoarthritis-related knee pain, and the iovera° system, a handheld cryoanalgesia device intended to temporarily block peripheral nerves and provide targeted pain relief.

Originally known as Pacira Pharmaceuticals, the company adopted the name Pacira BioSciences in 2018 to reflect its broader focus on innovative therapies and technologies.